Glucotrack, Inc.
No SEC Form 4 filings for $GCTK in the last 30 days.
See all $GCTK insider activity →Glucotrack (GCTK) announced a 1-for-15 reverse stock split, effective August 31, 2026, to meet Nasdaq's $1.00 minimum bid price requirement. Outstanding shares will reduce from 11.97 million to 798,144. The stock closed at $0.32, down 5.61%.
Lōkahi Therapeutics, a subsidiary of Glucotrack (GCTK), has initiated GMP manufacturing for LT-100, a honeybee-venom-derived biologic for osteoarthritis pain. The company aims to transition from 15 intradermal injections to a single subcutaneous injection per visit. GMP production is a key step in advancing LT-100 through clinical and regulatory milestones, with the first patient enrollment expected later this year, according to the company.
Glucotrack shareholders approved director elections, executive compensation, a reverse stock split, and warrant inducement at the 2026 annual meeting. The stock is down 94% over the past year, trading at $0.33 with a market cap of $2.13 million. The company completed a merger with Lōkahi Therapeutics and secured bridge financing. According to InvestingPro, GCTK appears overvalued.
Over the past 7 days, alphai's AI scored 2 news stories mentioning GCTK (Glucotrack, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent GCTK coverage spans corporate actions and financial news.
The reverse split will reduce share count and raise the per-share price, potentially improving liquidity and avoiding delisting.
Positive development milestone for LT-100 could improve long‑term valuation if trials succeed.
Potential dilution and price adjustment from reverse split and new warrants.
The reverse split will reduce share count and raise price per share, while the warrant repricing may dilute existing shareholders but provides liquidity.
Approval of a reverse stock split and warrant inducement may affect share count and liquidity.
alphai scores every news story that mentions GCTK with an AI model for sentiment and relevance, and aggregates insider trades from Glucotrack, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Glucotrack (GCTK) announced a 1-for-15 reverse stock split, effective August 31, 2026, to meet Nasdaq's $1.00 minimum bid price requirement. Outstanding shares will reduce from 11.97 million to 798,144. The stock closed at $0.32, down 5.61%.
1 min readLōkahi Therapeutics, a subsidiary of Glucotrack (GCTK), has initiated GMP manufacturing for LT-100, a honeybee-venom-derived biologic for osteoarthritis pain. The company aims to transition from 15 intradermal injections to a single subcutaneous injection per visit. GMP production is a key step in advancing LT-100 through clinical and regulatory milestones, with the first patient enrollment expected later this year, according to the company.
2 min readGlucotrack shareholders approved director elections, executive compensation, a reverse stock split, and warrant inducement at the 2026 annual meeting. The stock is down 94% over the past year, trading at $0.33 with a market cap of $2.13 million. The company completed a merger with Lōkahi Therapeutics and secured bridge financing. According to InvestingPro, GCTK appears overvalued.
2 min readGlucotrack (GCTK) held its 2026 annual meeting where shareholders approved a reverse stock split (up to 1-for-30) and a warrant inducement plan to comply with Nasdaq rules. Other proposals included director elections, advisory executive compensation vote, and auditor ratification. 36.10% of shares were voted.
2 min readGlucotrack, Inc. (GCTK) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. Summary of Proposals Submitted to Stockholders On August 18, 2026, Glucotrack, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the following proposals
2 min readGlucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry Into A Material Definitive Agreement. On August 7, 2026, Glucotrack, Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to the Common Stock Purchase Agreement, dated July 14, 2026 (the “ELOC Purchase Agreement”), by and between the Company and Whi
2 min readGlucotrack, Inc. (GCTK) filed an 8-K saying that on Aug. 4, 2026 it arranged follow-on financing totaling $5.5M through a $3.5M bridge follow-on and an interim PIPE. The bridge follow-on issued $3.5M senior secured convertible notes at 8% interest, with 22% OID, plus warrants, subject to stockholder approval for conversion and exercise.
4 min readGlucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Glucotrack Announces $5.5 Million Financing Includes $2.0 Million Equity Financing at $0.75 Per Unit, priced at a premium to the market, and $3.5 Million Follow-On Investment from Institutional Investors RUTHERFORD, N.J., and LA JOLLA, Calif., August 4, 2026 – Glucot
4 min readGlucoTrack, Inc. said it has a definitive agreement for a private placement with institutional investors. It plans to issue 2,666,666 units at $0.75 each, including one share and one five-year warrant priced at $1.50. The company expects total gross proceeds of about $5.5 million from equity and convertible debt.
2 min readGlucotrack Inc. said it raised about $5.5 million through institutional financing, including a $2.0 million equity investment priced at $0.75 per unit (share plus 5-year warrant at $1.50) and $3.5 million in follow-on convertible debt. The company plans to use proceeds to fund its implantable continuous blood glucose monitoring program and biopharmaceutical platform via Lōkahi Therapeutics.
4 min read
